Test Directory
BCR::ABL1 Tyrosine Kinase Domain Mutation Detection
Containers - Adult
Red Cap Tube EDTA KE 2.7ml
|
Volume Range
5-10ml Peripheral blood or bone marrow specimen
Additive per Container
EDTA |
Laboratory Site
Edinburgh
EH4 2XU
Transport arrangements
Blood and bone marrow specimens should ideally arrive within 24 hours of collection (maximum of 48 hours). Specimens should arrive no later than 3.30pm on Friday. Samples should be sent to the following address:
Western General Hospital
Haematology/Biochemistry Combined Reception
Immunophenotyping Laboratory
Crewe Road
Edinburgh
EH4 2XU
Sample storage arrangements
Samples should be stored at room temperature. See specimen requirements.
Special instructions for collection
How to request
Availability
Monday - Friday 9am-5pm
Anticipated turnaround
Results should be expected within 15 working days. See results.
Static information/disclaimer
This test has been accredited to ISO15189. However, part of the procedure now makes use of an automated pipetting system which has been separately validated but is not currently accredited to ISO 15189
General additional information
Mutations in the BCR::ABL1 kinase domain cause resistance to tyrosine kinase inhibitors (TKIs) in patients diagnosed with Chronic Myeloid Leukaemia (CML). This assay is designed to identify mutations within the BCR::ABL1 Kinase domain (including T315I).
The identification of mutations that confer resistance to TKIs may lead to a change in therapy for the patient.
For clinical advice on appropriate investigations and advice for the interpretation of test results, please contact us.